Exhibit 99.1 Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., – August 11, 2025 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2025, and provided business highlights. "The FDA's priority review of our BLA for tividenofusp alfa and alignment on an accelerated approval path for DNL126 are key milestones highlighting the potential of our Transport Vehicle (TV) platform to cata ...